Longer vs shorter abatacept doses to prevent graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 2 years old and weigh at least 10 kg
- You need a planned unrelated adult donor for the transplant (bone marrow or blood), with specific allowable mismatch details
- You (and your parent/guardian if needed) must be able to sign consent for the study
- Your cancer must be treatable with transplant and be in remission on standard tests
- You must have good day-to-day functioning (score about 80 or higher)
- You must not have certain excluded cancers or active relapse
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.